40353-62-6

Usage

Uses

Used in Pharmaceutical Industry:
CHEMBRDG-BB 9072017 is used as a research intermediate for the preparation of aminothiazoles, which are important compounds in the development of pharmaceuticals. These aminothiazoles have potential applications in the treatment of various diseases and disorders, making CHEMBRDG-BB 9072017 a crucial component in the drug discovery process.
Used in Chemical Research:
In the field of chemical research, CHEMBRDG-BB 9072017 is utilized as a key intermediate for the synthesis of various aminothiazoles. Its unique structure allows for the exploration of new chemical reactions and the development of novel compounds with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.
Used in Material Science:
CHEMBRDG-BB 9072017 can also be used in the development of new materials with specific properties, such as improved stability, reactivity, or selectivity. Its incorporation into the molecular structure of these materials can lead to the creation of advanced materials with potential applications in various fields, including electronics, energy storage, and catalysis.

InChI:InChI=1/C6H8N2OS/c1-3(9)5-4(2)10-6(7)8-5/h1-2H3,(H2,7,8)

Upstream product

• 21619-25-0 4-bromopentane-2,3-dione 
• 17356-08-0 thiourea 
• 600-14-6 2,3-Pentanedione 

Relevant academic research and scientific papers

Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design

The N-methyl-d-aspartate receptor (NMDAR) is a Na+ and Ca2+ permeable ionotropic glutamate receptor that is activated by the coagonists glycine and glutamate. NMDARs are critical to synaptic signaling and plasticity, and their dysfunction has been implicated in a number of neurological disorders, including schizophrenia, depression, and Alzheimer's disease. Herein we describe the discovery of potent GluN2A-selective NMDAR positive allosteric modulators (PAMs) starting from a high-throughput screening hit. Using structure-based design, we sought to increase potency at the GluN2A subtype, while improving selectivity against related α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). The structure-activity relationship of channel deactivation kinetics was studied using a combination of electrophysiology and protein crystallography. Effective incorporation of these strategies resulted in the discovery of GNE-0723 (46), a highly potent and brain penetrant GluN2A-selective NMDAR PAM suitable for in vivo characterization.

THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY

The present invention relates to certain thiazolopyrimidinone compounds for use in modulating NMDA receptor activity, pharmaceutical compositions comprising such compounds and methods of treating neurological and psychiatric conditions.

Azole derivatives as histamine H3 receptor antagonists, Part I: Thiazol-2-yl ethers

Most human histamine H3 receptor (hH3R) antagonists follow a general structural blueprint, containing a basic moiety linked by a spacer to a substituted core element. In this investigation the acceptance of thiazol-2-yl ether moieties in the core region is proved with some ether derivatives showing hH3R binding affinities in the nanomolar concentration range. A diversity of structural motifs is used as substituents to enhance the in vitro hH3R binding affinity.